Roy works as an interim consultant and has experience working as a CFO and financial manager in both unlisted and listed environments. He has solid experience from various leading positions in finance, accounting and business development and the last 15 years preferably with the various needs of listed companies such as acquisitions, divestments, issues, quarterly reporting and annual reports.
"It feels fantastically good and exciting to be part of Isofol's continued development journey and I hope to be able to contribute to the company reaching its goals," says Roy Jonebrant.
"We are delighted to welcome Roy to the Isofol team. His experience from listed companies will be very valuable to us," says Thomas Andersson, CEO of Isofol.
Roy starts his new position on March 27 and replaces Gustaf Albèrt, who was previously CFO and vice CEO.
For more information, please contact
Isofol Medical AB (publ)
Thomas Andersson, Chief Executive Officer
Phone: +46 (0) 709 44 00 93
The information was submitted for publication, through the agency of the contact person set out above, at 12.15 CET, on March 17, 2023.
About Isofol Medical AB (publ)
Isofol Medical AB (publ) is developing the drug candidate arfolitixorin with the aim of increasing the efficacy of current standard treatments for colorectal cancer and certain other tumor diseases. A Phase III study of arfolitixorin has been completed and the company is now evaluating opportunities to advance the drug candidate toward a marketing authorization application by conducting additional studies and entering potential partnerships. Isofol Medical AB (publ) is traded on Nasdaq Stockholm.